Quantoom and eTheRNA partner on a modular RNA production system

Quantoom and eTheRNA will work together to build an advanced, small-footprint technology platform for the production of affordable RNA-based therapies, which can be used in existing facilities or rapidly deployed in areas of urgent need.

eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies with in-house GMP-certified manufacturing and process development capabilities, and Quantoom Biosciences, a biotech focused on improving access to essential medicines through innovative methods innovative bioproduction facilities, will collaborate on the development of a revolutionary RNA Production System (RPS) for research and GMP-grade material.

Quantoom and eTheRNA will work together to build an advanced, small-footprint technology platform for the production of affordable RNA-based therapies, which can be used either in existing facilities or rapidly deployed in areas of urgent need. Unlike existing large and expensive RNA production plants, the RPS will manufacture small modular units of RNA, which can be shipped easily to multiple geographic regions.

The RPS is intended to scale seamlessly from small-scale preclinical batches to mass production of GMP-grade RNA. The only requirement will be that the RPS be located inside a suitable clean room with an uninterrupted power supply.

RPS is intended to scale seamlessly from small-scale preclinical batches to mass production of GMP-grade RNA

Under the terms of the agreement, eTheRNA will transfer manufacturing technology to Quantoom along with all materials and data needed to develop the new RPS.

After completion of the RPS, Quantoom will be responsible for marketing the system globally, with royalties related to the sales being payable to eTheRNA.

International sales and distribution are expected to begin in 2023 after RPS production in Belgium.

Bernard Sagaert, SVP Manufacturing and COO of eTheRNA, said, “This cooperation aligns with our RNA production goals of cost reduction, small to large scale process scalability, portability and process automation. Currently, the global supply of RNA is hampered by the lack of dedicated production facilities and the cost of building new factories.”

“RPS will revolutionize the way RNA is produced and distributed around the world and we are thrilled to be able to work with a leading developer and manufacturer like Quantoom to bring this vision to market,” added Sagaert.

Quantoom Biosciences is a team of scientists, engineers and clinicians bringing radical innovation to the production of vaccines and therapeutics, led by José Castillo, co-founder of Univercells. A serial entrepreneur, José previously co-founded Artelis, where he invented the iCellis bioreactor, which has become the industry standard for cell and gene therapy.

Companies